BETA - Welcome to our new website. We are continuing to make improvements and welcome your suggestions here.
ADVANCE
CONNECTING
AUSTRALIANS
GLOBALLY

Dr John McHutchison AO

Advance Awards Global Impact Winner

Professor Dr McHutchison AO has played a central and critical role in developing the curative treatments for Hepatitis C Virus (HCV). To develop this treatment is a remarkable accomplishment destined to improve the health of many millions of people. Leading the field with a commitment across all the incremental and seminal stages of discovery, John’s intellectual and clinical research talents resulted in him developing the antiviral drug combinations, Sovaldi®, Harvoni® and the more broad-spectrum anti-HCV (“pan-genotypic”) Epclusa® that collectively cure nearly every patient infected with HCV. This represents a 30-year personal investment as he has attempted to understand this disease. Having succeeded in this critical accomplishment, he has now turned his sights to curing HBV infection, of which there are 250 million infected people world-wide.

Dr. McHutchison joined Assembly Bio as Chief Executive Officer and President in 2019 and was also appointed as a Director. Assembly Bio is a clinical stage publicly traded biopharmaceutical company focused on oral therapeutics to cure hepatitis B infection. He most recently served as Chief Scientific Officer and Head of R&D at Gilead Sciences. During his nine years at Gilead he led the organisation in the successful filing of numerous New Drug Applications (NDAs) and supplemental label updates across multiple therapeutic areas. Dr. McHutchison received his degrees in medicine and surgery from the University of Melbourne in Australia, completed an internal medicine residency and gastroenterology fellowship at the Royal Melbourne Hospital, and a postdoctoral fellowship in Liver Diseases at the University of Southern California. He is a member of the Royal Australasian College of Physicians, and in 2018, he was appointed an Officer of the Order of Australia (AO).